MCID: DDF001
MIFTS: 49

Dedifferentiated Liposarcoma malady

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Dedifferentiated Liposarcoma

About this section
Sources:
51Orphanet, 65UMLS, 28ICD10 via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 51
Liposarcoma, Dedifferentiated 65
 
Ddls 51

Characteristics:

Orphanet epidemiological data:

51
dedifferentiated liposarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult

Classifications:

Orphanet: 51 
Rare tumors


External Ids:

Orphanet51 99970
ICD10 via Orphanet28 C49.9
UMLS via Orphanet66 C0205824
UMLS65 C0205824

Summaries for Dedifferentiated Liposarcoma

About this section
MalaCards based summary: Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to liposarcoma and primary malignant melanoma of the cervix. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways are Oncogene Induced Senescence and RB in Cancer. Affiliated tissues include t cells, bone and lung, and related mouse phenotypes are pigmentation and no phenotypic analysis.

Related Diseases for Dedifferentiated Liposarcoma

About this section

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 130)
idRelated DiseaseScoreTop Affiliating Genes
1liposarcoma11.0
2primary malignant melanoma of the cervix10.8CDKN2A, PTEN
3anaplastic ganglioglioma10.8MDM2, PTEN
4fibrosarcoma of bone10.7CDK4, MDM2
5small cell osteogenic sarcoma10.7CDK4, MDM2
6epithelioid sarcoma10.7CDK4, MDM2
7deep leiomyoma10.7ACTC1, CDKN2A
8autosomal dominant medullary cystic kidney disease with hyperuricemia10.7CDKN2A, PTEN
9angiolipoma10.7CDK4, CDKN2A, MDM2
10amelogenesis imperfecta hypomaturation type10.6CDKN2A, SDC1
11bowing of legs, anterior with dwarfism10.6CDKN2A, PPARG
12dubin-johnson syndrome10.6CDK4, CDKN2A, PTEN
13benign mesenchymoma10.6ACTC1, CDKN2A, PTEN
14middle ear squamous cell carcinoma10.6CDKN2A, MDM2
15malignant epithelial mesothelioma10.5ACTC1, CDKN2A
16pleomorphic xanthoastrocytoma10.5CDK4, CDKN2A, PTEN
17adult astrocytic tumour10.5MDM2, PPARG, PTEN
18autosomal dominant charcot-marie-tooth disease type 2f10.5IGF1R, PPARG, PTEN
19osteomyelitis10.5HMGA2, PTEN
20juvenile astrocytoma10.5CDK4, CDKN2A, MDM2, PTEN
21vibratory urticaria10.5CDKN2A, MET, PTEN
22bone peripheral neuroepithelioma10.5HMGA2, MDM2
23lupus erythematosus10.5MET, PPARG, PTEN
24acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor10.5CEBPA, KIT
25pacinian tumor10.5HMGA2, MDM2
26acute myeloid leukemia, kit-related10.4CEBPA, KIT
27gliosarcoma10.4CDK4, CDKN2A, MDM2, PTEN
28acute myeloblastic leukemia without maturation10.4CEBPA, KIT
29tendon sheath lipoma10.4CDK4, HMGA2, MDM2
30sebaceous breast carcinoma10.4CDK4, KIT, MDM2
31mucosal melanoma10.4KIT, PTEN
32vitamin d-dependent rickets, type i10.4CDK4, HMGA2, MDM2
33nezelof syndrome10.4CDK4, KIT, MDM2
34vesicoureteral reflux10.3CDKN2A, KIT, PTEN
35pleomorphic rhabdomyosarcoma10.3CDKN2A, IGF1R, MDM2
36brachyolmia10.3CDKN2A, KIT, PTEN
37sarcoma10.3
38histiocytoma10.3
39fibrous histiocytoma10.3
40cervical endometrial stromal sarcoma10.3ACTC1, HMGA2, MDM2
41facial injuries and disorders10.2MDM2, RB1
42pulmonary immaturity10.2ACTC1, DES, MDM2
43congenital fibrosis of the extraocular muscles10.2ACTC1, DES
44mixed liposarcoma10.2CDK4, CDKN2A, KIT, MDM2
45benign multicystic peritoneal mesothelioma10.2ACTC1, DES
46visual cortex disease10.2CDK4, CDKN2A, HMGA2, MDM2
47severe combined immune deficiency, autosomal recessive t cell-negative, b cell-positive, nk cell-positive, il7r-related10.2ACTC1, CDK4, DES
48pulmonary venous return anomaly10.2ACTC1, DES
49renal tubular acidosis, distal, autosomal recessive10.2DES, MET, PTEN
50ameloblastoma10.2CDKN2A, RB1

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to dedifferentiated liposarcoma

Symptoms for Dedifferentiated Liposarcoma

About this section

Drugs & Therapeutics for Dedifferentiated Liposarcoma

About this section

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Trabectedinapproved, investigationalPhase 258114899-77-3108150
Synonyms:
ET-743
ET743
Ecteinascidin
 
Ecteinascidin 743
NSC 684766
SID144206315
SID144206787
Yondelis
2
Rosiglitazoneapproved, investigationalPhase 2220122320-73-477999
Synonyms:
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
122320-73-4
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AC-3459
AC1L2U9N
Avandia
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
BRL49653
BSPBio_002693
Brl 49653
Brl-49653
C18H19N3O3S
CID77999
D08491
DB00412
Gaudil
Gaudil (TN)
HMS1922J11
HMS2094O13
HSDB 7555
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
KBioGR_001609
 
KBioSS_002183
LS-151340
MolPort-002-508-212
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
RSG
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone (INN)
Rosiglitazone Maleate
Rosiglitazone [INN:BAN]
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
S00306
SPBio_001142
SPECTRUM1504263
STOCK6S-23924
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
Spectrum_001703
TDZ 01
UNII-05V02F2KDG
[3H]rosiglitazone
rosiglitazona
rosiglitazone
rosiglitazone (Avandia)
rosiglitazonum
3PembrolizumabapprovedPhase 22881374853-91-4
4
IfosfamideapprovedPhase 23713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
5
MechlorethamineapprovedPhase 230951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
6
Maleic acidexperimentalPhase 2274110-16-7444972, 444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
7Antineoplastic Agents, AlkylatingPhase 23406
8Alkylating AgentsPhase 23582
9AntibodiesPhase 24477
10Hypoglycemic AgentsPhase 24503
11ImmunoglobulinsPhase 24477
12
MesnaPhase 22433375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
CoM
Coenzyme M
HS-CoM
13Isophosphamide mustardPhase 2371

Interventional clinical trials:

idNameStatusNCT IDPhase
1Selinexor in Advanced LiposarcomaRecruitingNCT02606461Phase 2, Phase 3
2Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated LiposarcomaRecruitingNCT02247544Phase 2
3Rosiglitazone in Treating Patients With LiposarcomaActive, not recruitingNCT00004180Phase 2
4Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical TrialActive, not recruitingNCT01692496Phase 2
5SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasActive, not recruitingNCT02301039Phase 2
6A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaNot yet recruitingNCT02571829Phase 2
7Ph II Cabazitaxel/Ifosfamide DD LiposarcomaSuspendedNCT01913652Phase 2
8Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialTerminatedNCT01876043Phase 2
9Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnNCT00969917Phase 2
10Phase 1 Safety Testing of SAR405838Active, not recruitingNCT01636479Phase 1

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Genetic Tests for Dedifferentiated Liposarcoma

About this section

Anatomical Context for Dedifferentiated Liposarcoma

About this section

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

33
T cells, Bone, Lung, Breast, Heart, Kidney, Prostate

Animal Models for Dedifferentiated Liposarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

38 (show all 28)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.1CDK4, CDKN2A, KIT, MDM2, PTEN, RB1
2MP:00030128.5CDKN2A, CEBPA, KIT, MDM2, MET, PPARG
3MP:00053718.3FRS2, IGF1R, KIT, MDM2, MET, PTEN
4MP:00053888.3CDKN2A, CEBPA, IGF1R, KIT, MET, PTEN
5MP:00053818.1CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
6MP:00028738.0ACTC1, CDK4, CEBPA, KIT, MDM2, MET
7MP:00053677.8CDK4, CEBPA, FRS2, KIT, MDM2, MET
8MP:00053907.7CDKN2A, FRS2, IGF1R, KIT, MDM2, PPARG
9MP:00053707.5CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
10MP:00053917.4CDK4, CDKN2A, CEBPA, FRS2, KIT, MET
11MP:00053867.2CDK4, CDKN2A, CEBPA, DES, IGF1R, KIT
12MP:00053807.1CALR, CDK4, CDKN2A, FRS2, IGF1R, KIT
13MP:00036317.0CALR, CDK4, CDKN2A, FRS2, IGF1R, KIT
14MP:00053797.0CDK4, CDKN2A, CEBPA, KIT, MDM2, MET
15MP:00107717.0CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
16MP:00053897.0CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
17MP:00020066.7CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
18MP:00053976.7CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
19MP:00053696.7ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
20MP:00053876.4CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2
21MP:00053856.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
22MP:00053786.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, FRS2
23MP:00053845.6ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
24MP:00053765.0ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES
25MP:00107684.9ACTC1, CALR, CDK4, CDKN2A, CEBPA, DES

Publications for Dedifferentiated Liposarcoma

About this section

Articles related to Dedifferentiated Liposarcoma:

(show top 50)    (show all 172)
idTitleAuthorsYear
1
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. (27124835)
2016
2
Multiple Primary Dedifferentiated Liposarcoma of the Jejunal Mesentery: A Case Report and Review of Literature. (26894164)
2016
3
Seaweed floating in the pericardium: a rare case of primary dedifferentiated liposarcoma. (26525285)
2015
4
Dedifferentiated Liposarcoma of the Anterior Mediastinum: A Rare Case. (26252913)
2015
5
Dedifferentiated Liposarcoma of the Gastroesophageal Junction. (25690861)
2015
6
Immunohistochemical, cytogenetic, and molecular cytogenetic characterization of both components of a dedifferentiated liposarcoma: implications for histogenesis. (25550570)
2015
7
Primary cardiac dedifferentiated liposarcoma with homologous and heterologous differentiation: a case report. (26464734)
2015
8
Dedifferentiated liposarcoma involving the spleen and splenic hilum: a report of a case with a rare growth pattern. (25594652)
2015
9
Primary dedifferentiated liposarcoma of the lung with rhabdomyoblastic and chrondroblastic differentiation. (24612243)
2014
10
Nuclear Expression of STAT6 in Dedifferentiated Liposarcomas With a Solitary Fibrous Tumor-like Morphology: A Diagnostic Pitfall. (25075469)
2014
11
Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients. (25287680)
2014
12
Loss of heterozygosity and microsatellite instability are rare in sporadic dedifferentiated liposarcoma: a study of 43 well-characterized cases. (24878023)
2014
13
Challenging dedifferentiated liposarcoma identified by MDM2-amplification, a report of two cases. (25126005)
2014
14
MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. (24515760)
2014
15
Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component. (23426961)
2013
16
High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. (23852861)
2013
17
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. (23569312)
2013
18
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. (23416162)
2013
19
Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. (22241790)
2012
20
Dedifferentiated liposarcoma of the rectum: a case report. (23139616)
2012
21
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. (23084521)
2012
22
Renal dedifferentiated liposarcoma with intra-caval tumor thrombus: A rare case. (22919143)
2012
23
Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. (22301498)
2012
24
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. (21793095)
2011
25
Primary (de novo) dedifferentiated liposarcoma in the extremities: a multi-institution Tohoku Musculoskeletal Tumor Society study of 18 cases in northern Japan. (21795247)
2011
26
Well-differentiated and dedifferentiated liposarcomas. (19688222)
2010
27
Dedifferentiated liposarcoma of retroperitoneum: spectrum of imaging findings in 15 patients. (20416485)
2010
28
Dedifferentiated liposarcoma of the retroperitoneum. (20369054)
2010
29
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. (19946100)
2009
30
Recurrent dedifferentiated liposarcoma of mediastinum involving lung and pleura. (19589790)
2009
31
Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component: report of two cases. (19135935)
2009
32
Dedifferentiated liposarcoma in the retroperitoneum in an atomic bomb survivor: report of a case. (21490866)
2008
33
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. (18214854)
2008
34
Dedifferentiated liposarcoma presenting as jejunal polyp. Case report. (18184419)
2007
35
Cytogenetic and molecular cytogenetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation. (17213023)
2007
36
Dedifferentiated liposarcoma of the pleura mimicking a malignant solitary fibrous tumor and associated with dedifferentiated liposarcoma of the mediastinum: usefulness of cytogenetic and molecular genetic analyses. (18036404)
2007
37
Dedifferentiated liposarcoma arising from the sigmoid mesocolon: a case report. (17696239)
2007
38
Surgery for dedifferentiated liposarcoma, presenting two radiologically and pathologically distinctive patterns. (16887838)
2006
39
alpha-fetoprotein expression in a dedifferentiated liposarcoma. (16489442)
2006
40
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. (16160477)
2005
41
Inguinal dedifferentiated liposarcoma with meningothelial-like whorls and metaplastic bone formation. (15842647)
2005
42
Primary dedifferentiated liposarcoma of the lung. (15910606)
2005
43
Alterations of the RB1 gene in dedifferentiated liposarcoma. (15933756)
2005
44
Dedifferentiated liposarcoma with extensive lymphoid component. (15991843)
2005
45
Best cases from the AFIP: Dedifferentiated liposarcoma of soft tissue with high-grade osteosarcomatous dedifferentiation. (16009825)
2005
46
Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. (12579306)
2003
47
A leukemoid reaction in a patient with a dedifferentiated liposarcoma. (11391379)
2001
48
Dedifferentiated liposarcoma with an inflammatory malignant fibrous histiocytoma-like component presenting a leukemoid reaction. (9311018)
1997
49
Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. (9071997)
1997
50
Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. (7977944)
1994

Variations for Dedifferentiated Liposarcoma

About this section

Expression for genes affiliated with Dedifferentiated Liposarcoma

About this section
Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Pathways for genes affiliated with Dedifferentiated Liposarcoma

About this section

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 39)
idSuper pathwaysScoreTop Affiliating Genes
19.8CDK4, CDKN2A, MDM2
29.6CDK4, MDM2, RB1
39.6CDKN2A, MDM2, RB1
49.6CDKN2A, MDM2, RB1
5
Show member pathways
9.6CDK4, CDKN2A, MDM2, PTEN
69.6CDK4, PTEN, RB1
79.5CDK4, IGF1R, RB1
89.4KIT, MET, PTEN
99.4CDK4, CDKN2A, MDM2, RB1
109.4CDK4, CDKN2A, MDM2, RB1
11
Show member pathways
9.4CDK4, CDKN2A, MDM2, RB1
129.4CDK4, CDKN2A, MDM2, RB1
139.4CDK4, MDM2, PTEN, RB1
14
Show member pathways
9.4CDK4, MDM2, PTEN, RB1
15
Show member pathways
9.4CDK4, MDM2, PTEN, RB1
169.3MDM2, MET, PTEN, RB1
179.3CDKN2A, HMGA2, MDM2, MET, PTEN
189.2IGF1R, KIT, MDM2, MET
19
Show member pathways
9.2IGF1R, MDM2, MET, PTEN, STAT6
209.2CALR, CDK4, CDKN2A, RB1
219.2CALR, MDM2, PTEN, RB1
22
Show member pathways
9.1CDK4, CDKN2A, MDM2, PTEN, RB1
239.0CDKN2A, IGF1R, MDM2, PTEN, RB1
249.0CEBPA, PPARG, RB1, STAT6
25
Show member pathways
8.9CALR, CDK4, PTEN, RB1, STAT6
26
Show member pathways
8.9CEBPA, IGF1R, KIT, MDM2, PTEN
27
Show member pathways
8.8CDK4, CDKN2A, MDM2, PSMD10, RB1
288.8CDK4, CDKN2A, IGF1R, MDM2, PTEN, RB1
298.8CEBPA, MDM2, MET, PPARG, RB1
30
Show member pathways
8.8CDK4, IGF1R, MDM2, MET, PTEN, RB1
318.8CEBPA, HMGA2, IGF1R, MDM2, MET, PPARG
328.7CDK4, IGF1R, KIT, MDM2, MET, PTEN
33
Show member pathways
8.5CDK4, CDKN2A, IGF1R, MDM2, MET, PTEN
34
Show member pathways
8.3CEBPA, IGF1R, KIT, MDM2, MET, PTEN
358.2FRS2, IGF1R, MDM2, MET, SDC1
368.2CEBPA, DES, KIT, PPARG, SDC1
37
Show member pathways
7.6CDK4, CEBPA, FRS2, KIT, MET, PPARG
38
Show member pathways
7.5CDK4, CDKN2A, DES, IGF1R, KIT, MDM2
397.3CDK4, CDKN2A, CEBPA, IGF1R, KIT, MDM2

GO Terms for genes affiliated with Dedifferentiated Liposarcoma

About this section

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1senescence-associated heterochromatin focus assemblyGO:003598610.7CDKN2A, HMGA2
2negative regulation of intracellular steroid hormone receptor signaling pathwayGO:003314410.5CALR, HMGA2
3negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.4CDKN2A, CEBPA
4white fat cell differentiationGO:005087210.4CEBPA, PPARG
5cellular response to lithium ionGO:007128510.3CALR, CEBPA
6protein localization to nucleusGO:003450410.3CALR, MDM2
7somatic stem cell divisionGO:004810310.3CDKN2A, KIT
8protein stabilizationGO:005082110.0CALR, CDKN2A, PTEN
9negative regulation of G1/S transition of mitotic cell cycleGO:200013410.0PTEN, RB1
10cell cycle arrestGO:000705010.0CALR, CDKN2A, RB1
11positive regulation of cell proliferationGO:00082849.8CDK4, HMGA2, MDM2, PTEN
12positive regulation of transcription, DNA-templatedGO:00458939.3CDKN2A, CEBPA, HMGA2, PPARG, RB1
13regulation of cell cycleGO:00517269.3CDK4, PTEN, RB1
14negative regulation of apoptotic processGO:00430669.2ACTC1, HMGA2, MDM2, PSMD10, PTEN
15phosphatidylinositol-mediated signalingGO:00480159.2FRS2, IGF1R, KIT, MDM2, PTEN
16response to toxic substanceGO:00096369.1CDK4, MDM2, SDC1
17regulation of transcription, DNA-templatedGO:00063559.1CALR, CEBPA, HMGA2, PPARG, STAT6
18negative regulation of transcription, DNA-templatedGO:00458929.0CALR, CEBPA, HMGA2, PPARG, RB1
19Fc-epsilon receptor signaling pathwayGO:00380958.9FRS2, MDM2, PSMD10, PTEN
20fibroblast growth factor receptor signaling pathwayGO:00085438.8FRS2, KIT, MDM2, PSMD10, PTEN
21signal transductionGO:00071658.6CDK4, HMGA2, IGF1R, KIT, MET, PPARG
22positive regulation of transcription from RNA polymerase II promoterGO:00459448.4CDKN2A, CEBPA, HMGA2, MET, PPARG, RB1

Sources for Dedifferentiated Liposarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet